Abstract: DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant erythropoietin and to methods of modifying or altering the regulating activity of a secretable erythropoietin and using modified secretable erythropoietin proteins.

Abstract: The invention provides isolated nucleic acids molecules, designated NPG-1 nucleic acid molecules, which encode polypeptides involved in the modulation of a response in a tumor cell. The invention also provides antisense nucleic acid molecules, expression vectors containing NPG-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an NPG-1 gene has been introduced or disrupted. The invention still further provides isolated NPG-1 polypeptides, fusion polypeptides, antigenic peptides, and anti-NPG-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides isolated nucleic acids molecules, designated NPG-1 nucleic acid molecules, which encode polypeptides involved in the modulation of a response in a tumor cell. The invention also provides antisense nucleic acid molecules, expression vectors containing NPG-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an NPG-1 gene has been introduced or disrupted. The invention still further provides isolated NPG-1 polypeptides, fusion polypeptides, antigenic peptides, and anti-NPG-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention relates to novel recombinant fusion proteins comprising two or more erythropoietin molecules. The fusion proteins can be linked by a peptide linker. The fusion proteins can be used, for example, to treat or prevent anemia in a mammal. Also disclosed are nucleotide sequences encoding the fusion proteins vectors comprising the nucleic acid sequences of the fusion proteins and host cells transfected with the vectors.

Abstract: Provided are nucleic acids encoding multimeric erythropoietin (EPO) proteins and having modifications in the 5′ and 3′ noncoding sequences relative to the corresponding sequences in native EPO DNA. The invention also relates to the use of such nucleic acids to produce multimeric EPO proteins, which may have altered activity as compared to EPO multimers expressed from nucleic acids having native 5′ and 3′ sequences.

Abstract: The invention provides isolated nucleic acids molecules, designated NPG-1 nucleic acid molecules, which encode polypeptides involved in the modulation of a response in a tumor cell. The invention also provides antisense nucleic acid molecules, expression vectors containing NPG-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an NPG-1 gene has been introduced or disrupted. The invention still further provides isolated NPG-1 polypeptides, fusion polypeptides, antigenic peptides, and anti-NPG-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: Provided are nucleic acids encoding erythropoietin (EPO) proteins and having modifications in the 5' and 3' noncoding sequences relative to the corresponding sequences in native EPO DNA. The invention also relates to the use of such nucleic acids to produce EPO proteins, which may have altered activity as compared to EPO proteins expressed from nucleic acids having native 5' and 3' sequences.

Abstract: The invention relates to novel modified polypeptides, with or without variations in noncoding regions, with altered biological activity. The invention discloses methods of preparing the modified polypeptides and methods of use.

Abstract: DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant erythropoietin and to methods of modifying or altering the regulating activity of a secretable erythropoietin and using modified secretable erythropoietin proteins.

Abstract: The invention relates to novel modified polypeptides, with or without variations in noncoding regions, with altered biological activity. The invention discloses methods of preparing the modified polypeptides and methods of use.

Abstract: Methods for identifying differentially expresses genes and differences between genomic nucleic acid sequences are described. These methods typically include: (a) providing a tester DNA molecule with an amplification tag at the 5' and 3' ends of the molecule and a driver DNA or RNA molecule lacking said amplification tag; (b) hybridizing said tester and said driver molecules to form a reaction mixture, wherein said reaction mixture comprises a tester--tester homoduplex, a tester-driver heteroduplex, a driver--driver homoduplex, a single stranded driver DNA molecule and a single stranded tester DNA molecule; (c) treating said reaction mixture to reduce the number of single stranded molecules in said mixture; (d) treating said reaction mixture to remove said amplification tag from said tester-driver heteroduplex; and (e) amplifying said tester--tester homoduplex from said reaction mixture to form an amplification product, wherein steps (c) and (d) occur before step (e).

Abstract: Modified polypeptides with increased biological activity exhibited as either increased potency or prolonged circulating half-life are disclosed with methods of preparing the modified polypeptides and methods of use.

Abstract: DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant erythropoietin and to methods of modifying or altering the regulating activity of a secretable erythropoietin and using modified secretable erythropoietin proteins.

Abstract: Modified polypeptides with increased biological activity exhibited as either increased potency or prolonged circulating half-life are disclosed with methods of preparing the modified polypeptides and methods of use.

Abstract: Protein immunoassay or purification using an antibody raised to an antigen comprising a polypeptide corresponding to a fragment (but not all) of the protein being assayed; the antibody is capable of binding separately both to the protein as a whole and to the polypeptide; that antibody is used to purify or (with a known concentration of the labeled polypeptide serving as a tracer) to assay the protein.